What’s In An Abstract? A Preview Of ASCO Annual Meeting Highlights

Data supporting first-line use of Lilly's Alimta in non-small cell lung cancer and GlaxoSmithKline's data on combining two targeted oncologics - Tykerb and Herceptin - are among the highlights of the massive data drop from the upcoming American Society of Clinical Oncology annual meeting